Literature DB >> 17453713

The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting.

Jorge Correale1, Andrés Villa.   

Abstract

In most regions of the central nervous system (CNS), the composition of the neuronal microenvironment is maintained by virtue of particular blood-brain-barrier (BBB) characteristics, to which vascular endothelial cells (ECs) contribute an important role. Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS, characterized at tissue level by multifocal perivascular infiltrates, predominantly of lymphocytes and macrophages. Thus, lymphocyte recruitment into the brain across ECs of the BBB represents a critical event in disease pathogenesis, which is highly restricted and carefully regulated. In recent years, different investigations have identified the crucial components involved in leukocyte migration, providing new insights into mechanisms modulating neuroinflammatory reactions. In this review, several topics relating to these events are discussed, namely: (1) cellular and molecular characteristics of the BBB regulating permeability, as well as signals inducing EC differentiation in the brain and specific cell properties; (2) pathogenic mechanisms guiding the migration of different leukocyte populations through the BBB in MS; and (3) current knowledge on how different MS therapies targeting leukocytes migration across the BBB function. Furthermore, because the BBB has proven to be an important retaining wall preventing drug passage into the CNS, novel strategies directed at successful delivery of large molecules for effective treatment of various inflammatory conditions of the brain, both currently available or still under development, are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453713     DOI: 10.1080/08916930601183522

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  38 in total

Review 1.  Neurovascular unit: a focus on pericytes.

Authors:  Inês Sá-Pereira; Dora Brites; Maria Alexandra Brito
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

Review 2.  Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.

Authors:  Yukio Takeshita; Richard M Ransohoff
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

Review 4.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

Review 5.  Microbiota and the control of blood-tissue barriers.

Authors:  Maha Al-Asmakh; Lars Hedin
Journal:  Tissue Barriers       Date:  2015-05-29

6.  Human brain endothelial cells are responsive to adenosine receptor activation.

Authors:  Jeffrey H Mills; Leah Alabanza; Babette B Weksler; Pierre-Olivier Couraud; Ignacio A Romero; Margaret S Bynoe
Journal:  Purinergic Signal       Date:  2011-02-17       Impact factor: 3.765

Review 7.  TREK-king the blood-brain-barrier.

Authors:  Stefan Bittner; Tobias Ruck; Juncal Fernández-Orth; Sven G Meuth
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-21       Impact factor: 4.147

Review 8.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 9.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

Review 10.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.